<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525876</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0309</org_study_id>
    <nct_id>NCT00525876</nct_id>
  </id_info>
  <brief_title>Non-Myeloablative Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen for Advanced/Recurrent Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell
           transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen
           for patients with advanced or recurrent mantle cell lymphoma.

        2. To determine factors associated with response and durable remission in patients
           receiving rituximab, cyclophosphamide, and fludarabine in preparation for allogeneic
           stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MATCHED SIBLING TRANSPLANTS:

      If you are found to be eligible to take part in this study, you will be admitted to the
      hospital to receive treatment. Two (2) chemotherapy drugs, fludarabine and cyclophosphamide,
      will be given each day for 3 days. The drugs will be given one at a time in a vein. Each
      treatment will take about 30 minutes. Fludarabine will be given first, and cyclophosphamide
      will be given 4 hours later. You will receive rituximab once a week for 4 weeks by vein over
      4-8 hours. The first dose will starts one week before starting the chemotherapy.

      Two days after finishing chemotherapy, you will receive a transplant of stem cells from a
      sibling. The stem cells will be infused into your vein. Seven days later, you will begin to
      receive a drug called granulocyte colony-stimulating factor (G-CSF). G-CSF helps the new stem
      cells do their normal work in the body;making new blood cells. You will receive G-CSF each
      day until your blood cell counts begin to recover to a certain level.

      Sometimes the donor cells cause inflammation of the skin, liver and gut, and a reaction
      called graft-versus-host disease occurs. The drugs tacrolimus and methotrexate will be given
      to help decrease the risk of this. These drugs are also given through a vein before and after
      transplant . Tacrolimus will be infused two days before transplant and will continue to be
      given daily as a continuous infusion. Methotrexate will be given through the vein as a short
      infusion on Days 1, 3, and 6 after the transplant. Tacrolimus also comes in pill form, and
      you may switch to the pills when ready.

      During your hospitalization, you will be examined daily, and blood (about 1 tablespoon)
      samples will be taken daily to evaluate your blood count levels, the function of your liver
      and kidneys, as well as electrolytes. This blood will also be used to measure tacrolimus
      levels and to look for any infections. You might be given blood transfusions if blood cell
      counts remain low.

      MATCHED UNRELATED OR MISMATCHED SIBLING TRANSPLANTS:

      Alemtuzumab is a drug that is designed to specifically attack some types of leukemia and
      lymphoma cells. In addition, it weakens the immune system, helping to prevent the rejection
      of donor marrow or stem cells.

      TBI is designed to damage the DNA (the genetic material of cells) of cancer cells, which may
      kill the cancer cells.

      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may
      slow or stop their growth and spread throughout the body. This may cause the cancer cells to
      die.

      Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may
      increase the likelihood of the cells dying.

      Rituximab is designed to attach to lymphoma cells, which may cause them to die.

      If you are found to be eligible to take part in this study, you will be admitted to the
      hospital for treatment. Alemtuzumab will be injected into your vein over a period of 4 hours.
      This will be done 3 days in a row (Days 1 to 3). Drugs diphenhydramine (Benadryl), solumedrol
      and acetaminophen (Tylenol) will be given in to decrease the risk of or ease side effects
      before each dose of the alemtuzumab.

      You will also receive fludarabine and cyclophosphamide once a day for 3 days. They will be
      given on the same days as alemtuzumab. Both drugs will be given through a catheter (plastic
      tube) that extends into the large chest vein. The catheter will be left in place throughout
      treatment on this study. Some participants, depending on their type of disease, will also
      receive rituximab. Rituximab will be given 8 days before the transplant and then once a week
      for a total of 4 doses.

      After completion of chemotherapy, you will receive TBI, and later on the same day, blood stem
      cells from a donor will be given through the catheter. G-CSF, a growth factor that promotes
      the production of blood cells, will be injected under the skin once a day until your blood
      cell counts recover to a certain level.

      Blood tests (about 2 tablespoons each) , urine tests, bone marrow aspirations, and x-rays
      will be done as needed to track the effects of the transplant. The blood tests will be drawn
      daily while in the hospital and then at least twice weekly as an outpatient for the first 100
      days. The CT scans and bone marrow studies will be done at 1, 3, 6, and 12 months and then
      every 6 months for at least 3 years after transplant. You may also have transfusions of blood
      and platelets as needed.

      IMMUNOMODULATION POST NONABLATIVE STEM CELL TRANSPLANTATION FOR PATIENTS WITH LYMPHOID
      MALIGNANCIES:

      You will receive treatment as an outpatient. You will receive rituximab over 4 - 8 hours
      through a vein once a week for 4 weeks. You will also get a boost of cells from the same
      donor from whom you received the original transplant. These additional cells will be infused
      through the vein (over 30 - 60 minutes) between the second and the third dose of rituximab.
      The infusion may have to be done later if cells were not available as scheduled.

      Sometimes the donor cells cause inflammation of the skin, liver and gut, and a reaction
      called graft-versus-host disease occurs. If this happens, the drug tacrolimus and
      methotrexate will be given to help control this reaction. These medications are usually given
      by pills on a daily basis.

      A boost with a higher number of cells may be infused once a month for 3 months if there is no
      graft-versus-host disease and if disease remains.

      During treatment, you will be examined as needed, and blood samples (1 tablespoon once or
      twice a week) will be taken for routine tests. You may need to receive blood transfusions
      during this study if your blood cell counts remain low.

      About 40 patients will take part in this study, and all will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival at 100 Days Post Transplant (Number of Surviving Participants)</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Overall Survival defined as the number of participants living at day 100 following non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for participants with advanced or recurrent mantle cell lymphoma.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Matched Sibling Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allo MUD &amp; MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo MUD &amp; MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Matched Donors:
750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.
Unrelated or Mismatched Donors:
1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)</description>
    <arm_group_label>Matched Sibling Transplant</arm_group_label>
    <arm_group_label>Allo MUD &amp; MM</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)</description>
    <arm_group_label>Matched Sibling Transplant</arm_group_label>
    <arm_group_label>Allo MUD &amp; MM</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Matched Donors:
375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
Unrelated/Mismatched Donors:
375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.
DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:
375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease.</description>
    <arm_group_label>Matched Sibling Transplant</arm_group_label>
    <arm_group_label>Allo MUD &amp; MM</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Unrelated/Mismatched Donors:
15 mg per day given intravenously days 1 through 3 after transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)</description>
    <arm_group_label>Allo MUD &amp; MM</arm_group_label>
    <other_name>CAMPATH-1H</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Stem Cell Infusion</intervention_name>
    <description>Infusion of stem cells.</description>
    <arm_group_label>Matched Sibling Transplant</arm_group_label>
    <arm_group_label>Allo MUD &amp; MM</arm_group_label>
    <other_name>ASCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients can be as old as 70 years.

          2. They must have a diagnosis of MCL, either (1) Recurrent, (2) Newly diagnosed (after
             cytoreduction with conventional chemotherapy) but with high-risk features (blastic or
             blastoid features, leukemic phase, or elevated B^2 microglobulin (&gt; 3).

          3. Patients that have received prior conventional chemotherapy but have not achieved
             complete response (CR).

          4. Disease must be chemosensitive, (ie, patients must not have had a partial response to
             prior therapy).

          5. Patients whose disease failed to respond to a previous autologous transplantation may
             also be eligible.

          6. Patients must have a matched or 1 antigen mismatched sibling or unrelated donor.

          7. Point Scale (PS) &lt;/= 2.

          8. Inclusion criteria for Immunomodulation Post transplantation: Patients can be as old
             as 70 years. Patients must have a diagnosis of MCL or CLL with one of the following
             characteristics: 1. Patients who develop disease progression or do not experience a CR
             within 3 months post-allogeneic transplantation 2. Patients with a weak chimerism (any
             mixed chimerism of donor T cells in patients receiving Campath by day 90, and less
             than 20% for patients not receiving Campath) or a drop of 20% or more with an amount
             of donor cells present in the blood &lt; 50% by PCR .

          9. Continued from Inclusion # 8: Patients must have the same donor of the original
             transplant willing to donate lymphocytes. 4. PS &lt;/ 2.

        Exclusion Criteria:

          1. Past history of anaphylaxis following exposure to rat- or mouse-derived CDR-grafted
             humanized monoclonal antibodies.

          2. Less than 4 weeks since prior chemotherapy counted from first day of treatment
             regimen.

          3. Pregnancy or lactation.

          4. HIV or HTLV-I positivity.

          5. Serum creatinine concentration &gt; 1.6 mg/dl or serum bilirubin &gt; 2.0 mg/dl unless due
             to tumor

          6. pulmonary function test - carbon monoxide diffusing capacity &lt; 40%

          7. cardiac ejection fraction &lt; 40% of predicted levels (by multiple-gated acquisition or
             echocardiography).

          8. Severe concomitant medical or psychiatric illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <results_first_submitted>November 2, 2011</results_first_submitted>
  <results_first_submitted_qc>November 2, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2011</results_first_posted>
  <last_update_submitted>November 2, 2011</last_update_submitted>
  <last_update_submitted_qc>November 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Neosar</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludara</keyword>
  <keyword>Fludarabine phosphate</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>CAMPATH-1H</keyword>
  <keyword>Campath</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>TBI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period:1/27/2005 through 8/31/2010. All participant recruitment attempted at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Out of the 49 participants enrolled, 13 were excluded, not assigned to part of the two intervention study groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Matched Sibling Transplant</title>
          <description>Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.</description>
        </group>
        <group group_id="P2">
          <title>Allo MUD &amp; MM</title>
          <description>Allo MUD &amp; MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Matched Sibling Transplant</title>
          <description>Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.</description>
        </group>
        <group group_id="B2">
          <title>Allo MUD &amp; MM</title>
          <description>Allo MUD &amp; MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="7"/>
                    <measurement group_id="B2" value="59" spread="6"/>
                    <measurement group_id="B3" value="59" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival at 100 Days Post Transplant (Number of Surviving Participants)</title>
        <description>Overall Survival defined as the number of participants living at day 100 following non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for participants with advanced or recurrent mantle cell lymphoma.</description>
        <time_frame>100 days post transplant</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Matched Sibling Transplant</title>
            <description>Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.</description>
          </group>
          <group group_id="O2">
            <title>Allo MUD &amp; MM</title>
            <description>Allo MUD &amp; MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 100 Days Post Transplant (Number of Surviving Participants)</title>
          <description>Overall Survival defined as the number of participants living at day 100 following non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for participants with advanced or recurrent mantle cell lymphoma.</description>
          <population>Analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Matched Sibling Transplant</title>
          <description>Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.</description>
        </group>
        <group group_id="E2">
          <title>Allo MUD &amp; MM</title>
          <description>Allo MUD &amp; MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged Hospitalization due to Graft vs Host Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspergillus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>CMV Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <description>Tongue swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Extremity Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decreased Left Ventricular Ejection Fraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lower GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Graft versus Host Disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issa F. Khouri, MD/ Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>celsaenz@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

